Abstract
Nonalcoholic fatty liver disease (NAFLD) is a globally widespread disease of increasing clinical significance. The pathological progression of the disease from simple steatosis to nonalcoholic steatohepatitis (NASH) has been well defined, however, the contribution of altered branched chain amino acid metabolomic profiles to the progression of NAFLD is not known. The three BCAAs: leucine, isoleucine and valine are known to mediate activation of several important hepatic metabolic signaling pathways ranging from insulin signaling to glucose regulation. The purpose of this study is to profile changes in hepatic BCAA metabolite levels with transcriptomic changes in the progression of human NAFLD to discover novel mechanisms of disease progression. Metabolomic and transcriptomic data sets representing the spectrum of human NAFLD (normal, steatosis, NASH fatty, and NASH not fatty livers) were utilized for this study. During the transition from steatosis to NASH, increases in the levels of leucine (127 % of normal), isoleucine (139 %), and valine (147 %) were observed. Carnitine metabolites also exhibited significantly elevated profiles in NASH fatty and NASH not fatty samples and included propionyl, hexanoyl, lauryl, acetyl and butyryl carnitine. Amino acid and BCAA metabolism gene sets were significantly enriched among downregulated genes during NASH. These cumulative alterations in BCAA metabolite and amino acid metabolism gene profiles represent adaptive physiological responses to disease-induced hepatic stress in NASH patients.
Similar content being viewed by others
References
Adams SH (2011) Emerging perspectives on essential amino acid metabolism in obesity and the insulin-resistant state. Adv Nutr Int Rev J 2(6):445–456
Adeva MM, Calvino J, Souto G, Donapetry C (2012) Insulin resistance and the metabolism of branched-chain amino acids in humans. Amino Acids 43(1):171–181
Ali R, Cusi K (2009) New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). Ann Med 41(4):265–278
Bellentani S, Scaglioni F, Marino M, Bedogni G (2010) Epidemiology of non-alcoholic fatty liver disease. Dig Dis 28(1):155–161
Bodoy S, Fotiadis D, Stoeger C, Kanai Y, Palacin M (2012) The small SLC43 family: facilitator system L amino acid transporters and the orphan EEG1. Mol Aspects Med 12:S0098–S2997
Bonora E (2006) The metabolic syndrome and cardiovascular disease. Ann Med 38:64–80
Boujedidi H, Bouchet-Delbos L, Cassard-Doulcier AM, Njike-Nakseu M, Maitre S, Prevot S, Dagher I, Agostini H, Voican CS, Emilie D, Perlemuter G, Naveau S (2012) Housekeeping gene variability in the liver of alcoholic patients. Alcohol Clin Exp Res 36(2):258–266
Congiu M, Slavin JL, Desmond PV (2011) Expression of common housekeeping genes is affected by disease in human hepatitis C virus-infected liver. Liver Int 31(3):386–390
Dam-Larsen S (2004) Long-term prognosis of fatty liver: risk of chronic liver disease and death. Gut 53:750–755
Day CP (2002) Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol 16(5):663–678
Day CP, James OFW (1998) Steatohepatitis: a tale of two ‘‘hits’’? Gastroenterology 114(4):842–845
Dodd KM, Tee AR (2012) Leucine and mTORC1: a complex relationship. Am J Physiol Endocrinol Metabol 302(11):E1329–E1342
Fabbrini E, Sullivan S, Klein S (2010) Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 51:679–689
Fisher CD, Lickteig AJ, Augustine LM, Ranger-Moore J, Jackson JP, Ferguson SS, Cherrington NJ (2009) Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab Dispos 37(10):2087–2094
Fukuhara D, Kanai Y, Chairoungdua A, Babu E, Bessho F, Kawano T, Akimoto Y, Endou H, Yan K (2007) Protein characterization of Na+-independent system L amino acid transporter 3 in mice—a potential role in supply of branched-chain amino acids under nutrient starvation. Am J Pathol 170(3):888–898
Greco D, Kotronen A, Westerbacka J, Puig O, Arkkila P, Kiviluoto T, Laitinen S, Kolak M, Fisher RM, Hamsten A, Auvinen P, Yki-Jarvinen H (2008) Gene expression in human NAFLD. Am J Physiol Gastrointest Liver Physiol 294(5):G1281–G1287
Hagiwara A, Nishiyama M, Ishizaki S (2012) Branched-chain amino acids prevent insulin-induced hepatic tumor cell proliferation by inducing apoptosis through mTORC1 and mTORC2-dependent mechanisms. J Cell Physiol 227(5):2097–2105
Hardwick RN, Fisher CD, Canet MJ, Scheffer GL, Cherrington NJ (2011) Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease. Drug Metab Dispos 39(12):2395–2402
Hardwick RN, Ferreira DW, More VR, Lake AD, Lu Z, Manautou JE, Slitt AL, Cherrington N (2012) Altered UDP-glucuronosyltransferase (UGT) and sulfotransferase (SULT) expression and function during progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos 41(3):554–661
Hayaishi S, Chung H, Kudo M, Ishikawa E, Takita M, Ueda T, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Ueshima K (2011) Oral branched-chain amino acid granules reduce the incidence of hepatocellular carcinoma and improve event-free survival in patients with liver cirrhosis. Dig Dis 29(3):326–332
Hnatyshyn S, Shipkova P, Sanders M (2013) Expedient data mining for nontargeted high-resolution LC-MS profiles of biological samples. Bioanalysis 5(10):1195–1210
Kalhan SC, Guo L, Edmison J, Dasarathy S, McCullough AJ, Hanson RW, Milburn M (2011) Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism 60(3):404–413
Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41(6):1313–1321
Koehler EM, Schouten JNL, Hansen BE, van Rooij FJA, Hofman A, Stricker BH, Janssen HLA (2012) Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam study. J Hepatol 57(6):1305–1311
Lake AD, Novak P, Fisher CD, Jackson JP, Hardwick RN, Billheimer DD, Klimecki WT, Cherrington NJ (2011) Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos 39(10):1954–1960
Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N (2001) Nonalcoholic fatty liver disease—a feature of the metabolic syndrome. Diabetes 50(8):1844–1850
Mariotta L, Ramadan T, Singer D, Guetg A, Herzog B, Stoeger C, Palacin M, Lahoutte T, Camargo SMR, Verrey F (2012) T-type amino acid transporter TAT1 (Slc16a10) is essential for extracellular aromatic amino acid homeostasis control. J Physiol 590(24):6413–6424
McCullough AJ (2006) Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 40:S17–S29
McCullough AJ (2011) Epidemiology of the metabolic syndrome in the USA. J Dig Dis 12(5):333–340
Merrell MD, Cherrington NJ (2011) Drug metabolism alterations in nonalcoholic fatty liver disease. Drug Metab Rev 43(3):317–334
Miyake T, Abe M, Furukawa S, Tokumoto Y, Toshimitsu K, Ueda T, Yamamoto S, Hirooka M, Kumagi T, Hiasa Y, Matsuura B, Onji M (2012) Long-term branched-chain amino acid supplementation improves glucose tolerance in patients with nonalcoholic steatohepatitis-related cirrhosis. Intern Med 51(16):2151–2155
Nagao Y, Kawaguchi T, Ide T, Sata M (2012) Effect of branched-chain amino acid-enriched nutritional supplementation on interferon therapy in Japanese patients with chronic hepatitis C virus infection: a retrospective study. Virol J 9(1):282
Newgard C (2012) Interplay between lipids and branched-chain amino acids in development of insulin resistance. Cell Metab 15(5):606–614
Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD, Lien LF, Haqq AM, Shah SH, Arlotto M, Slentz CA, Rochon J, Gallup D, Ilkayeva O, Wenner BR, Yancy J, Eisenson H, Musante G, Surwit RS, Millington DS, Butler MD, Svetkey LP (2009) A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 9(4):311–326
Rubinstein E, Lavine JE, Schwimmer JB (2008) Hepatic, cardiovascular, and endocrine outcomes of the histological subphenotypes of nonalcoholic fatty liver disease. Semin Liver Dis 28(4):380–385
Schooneman MG, Vaz FM, Houten SM, Soeters MR (2013) Acylcarnitines: reflecting or inflicting insulin resistance? Diabetes 62(1):1–8
She P, Van Horn C, Reid T, Hutson SM, Cooney RN, Lynch CJ (2007) Obesity-related elevations in plasma leucine are associated with alterations in enzymes involved in branched-chain amino acid metabolism. Am J Physiol Endocrinol Metabol 293(6):E1552–E1563
She P, Olson KC, Kadota Y, Inukai A, Shimomura Y (2013) Leucine and protein metabolism in obese Zucker rats. PLoS One 8(3):e59443
Suryawan A, Hawes JW, Harris RA, Shimomura Y, Jenkins AE, Hutson SM (1998) A molecular model of human branched-chain amino acid metabolism. Am J Clin Nutr 68(1):72–81
Sweatt AJ, Wood M, Suryawan A, Wallin R, Willingham MC, Hutson SM (2004) Branched-chain amino acid catabolism: unique segregation of pathway enzymes in organ systems and peripheral nerves. Am J Physiol Endocrinol Metabol 286(1):E64–E76
Tajiri K, Shimizu Y (2013) Branched-chain amino acids in liver diseases. World J Gastroenterol 19(43):7620–7629
Takanaga H, Mackenzie B, Peng JB, Hediger MA (2005) Characterization of a branched-chain amino-acid transporter SBAT1 (SLC6A15) that is expressed in human brain. Biochem Biophys Res Commun 337(3):892–900
Wong VWS, Chu WCW, Wong GLH, Chan RSM, Chim AML, Ong A, Yeung DKW, Yiu KKL, Chu SHT, Woo J, Chan FKL, Chan HLY (2012) Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 61(3):409–415
Yoshida R, Yagi T, Sadamori H, Matsuda H, Shinoura S, Umeda Y, Sato D, Utsumi M, Nagasaka T, Okazaki N, Date A, Noguchi A, Tanaka A, Hasegawa Y, Sakamoto Y, Fujiwara T (2012) Branched-chain amino acid-enriched nutrients improve nutritional and metabolic abnormalities in the early post-transplant period after living donor liver transplantation. J Hepato Biliary Pancreat Sci 19(4):438–448
Acknowledgments
We extend our sincere gratitude to Dr. Walter T. Klimecki for his valued scientific advice and contribution to the development of the human NAFLD microarray data set. We also thank Jose Munoz-Rodriguez and the Genomics Core Facility at the University of Arizona Cancer Center for the processing, archiving, and data acquisition of the microarrays. The authors also thank the National Institutes of Health (NIH)-sponsored Liver Tissue Cell Distribution System members for their help in the acquisition of human liver tissue at the University of Minnesota, Virginia Commonwealth and the University of Pittsburgh. This work was supported by the National Institutes of Health Grants, [AI083927], [HD062489], [ES006694]; the National Institute of Environmental Health Science Toxicology Training Grant [ES007091]; the Academy of Sciences of the Czech Republic with institutional support [RVO:60077344], and the Liver Tissue Cell Distribution System National Institutes of Health Contract [NO1-DK-7-0004/HHSN267200700004C].
Conflict of interest
The authors declare that there are no conflicts of interest, financial or otherwise that would influence the performance or presentation of work in this manuscript.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Lake, A.D., Novak, P., Shipkova, P. et al. Branched chain amino acid metabolism profiles in progressive human nonalcoholic fatty liver disease. Amino Acids 47, 603–615 (2015). https://doi.org/10.1007/s00726-014-1894-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00726-014-1894-9